
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedys groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders. Remedys lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024
Cancer drug development,biotechnology,cancer containment therapy,and cancer stem cells
Remedy plan therapeutics operates in the Biotechnology industry.
Remedy plan therapeutics's revenue is 1m - 10m
Remedy plan therapeutics has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.